Pediatric Vaccines: Epidemiology Forecast to 2028

2019-05-31
Price :
Published : May-2019
No. of Pages : 40

Pediatric Vaccines: Epidemiology Forecast to 2028

Summary

The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year.

GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at a meaningful, in-depth analysis and forecast of pediatric vaccination rates. Moreover, GlobalData epidemiologists provide detailed dose- and age-specific vaccination rates, dependent on the specific vaccine and routine immunization requirements of each market.

GlobalData epidemiologists forecast that the average pediatric vaccination rates in the combined 9MM will increase from 86.89% in 2018 to 88.67% in 2028; this represents an almost 90% compliance with children at or under age two years receiving the routine vaccinations required by each market. The major drivers behind this increase are Italy’s new law expanding mandatory childhood vaccines from four to 10, as well as the large number of newly adopted vaccines in both Japan and India, which are expected to see an increase in vaccination rates over time. Lastly, in comparing the three geographic regions covered by this forecast in 2018, North American markets had an average vaccination rate of 83%, European markets had an average vaccination rate of 93%, and Asian markets had an average vaccination rate of 80%. In the future, continued efforts should focus on carrying out a targeted, actionable, and effective country-specific approach to overcome vaccine hesitancy, and ultimately increase vaccination rates that show signs of a plateau or decline.

Scope

– The Pediatric Vaccines Epidemiology Report and Model provide an overview of the risk factors and global trends of pediatric vaccines in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Canada, and India).
– This report also includes a 10-year epidemiological forecast for the vaccinated pediatric population segmented by vaccine, dosing, and age in these nine markets. Dosing and age groups included within the forecast were dependent on the specific vaccine, routine immunization requirements in each market, and availability of vaccination data. Across markets, dose- and age-specific vaccination rates were obtained for children ranging from age zero years (0-12 months) to age seven years (85-96 months), and covered the following vaccines/vaccine combinations: diphtheria, tetanus, pertussis, diphtheria/tetanus/pertussis (DTaP), inactivated poliovirus vaccine (IPV), oral poliovirus vaccine (OPV), diphtheria/tetanus/IPV (DT-IPV), Haemophilus influenzae Type B (Hib), DTaP/IPV/Hib, Hib/meningitis C, hepatitis A (hep A), hepatitis B (hep B), measles/mumps/rubella (MMR), measles, mumps, rubella, measles/rubella (MR), rotavirus, varicella, and Japanese encephalitis (JE).
– The Pediatric Vaccines epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
– The Epidemiology Model is easy to navigate, interactive, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Pediatric Vaccines Epidemiology series will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global pediatric vaccines market.
– Quantify patient populations in the global pediatric vaccines market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for pediatric vaccine therapeutics in each of the markets covered.
– Understand magnitude of the pediatric vaccines population by vaccine, dose, and age.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

B-Cell Non-Hodgkin’s Lymphoma: Epidemiology Forecast to 2027

B-Cell Non-Hodgkin's Lymphoma: Epidemiology Forecast to 2027 Summary Non-Hodgkin's lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the patient's immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body's inability to fight infections and other diseases. NHL accounts for 90% of all malignant lymphomas. NHL is one of the most prevalent hematologic cancers in adults and is more commonly diagnosed in developed countries. B-cell lymphomas are the most common form of NHL diagnosed in developed countries, making up approximately 80-85% of NHL cases in the US. GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent ......
$3995

Post-Traumatic Stress Disorder: Epidemiology Forecast to 2028

Post-Traumatic Stress Disorder: Epidemiology Forecast to 2028 Summary Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, rape, or other violent personal assault (American Psychiatric Association, 2018). PTSD affects as many as one in four people who experience traumatic events, and contributes to marked functional disability, health impairment, and social dysfunction. People with PTSD may relive the event via intrusive memories, flashbacks, and nightmares; avoid anything that reminds them of the trauma; and have anxious feelings they didn't have before (North, Hong and Downs, 2018). GlobalData epidemiologists utilized nati......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides......
$1000

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products Summary An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
$6995

Digital Therapeutics and Their Impact on Healthcare

Digital Therapeutics and Their Impact on Healthcare Summary Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions. This report provides an overview of cur......
$7995

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends – Q1 2019

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019 Summary GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Italy

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Down Syndrome Global Clinical Trials Review, H1, 2019

Down Syndrome Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Down Syndrome Global Clinical Trials Review, H1, 2019" provides an overview of Down Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Down Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Endometrial Hyperplasia Global Clinical Trials Review, H1, 2019

Endometrial Hyperplasia Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Endometrial Hyperplasia Global Clinical Trials Review, H1, 2019" provides an overview of Endometrial Hyperplasia clinical trials scenario. This report provides top line data relating to the clinical trials on Endometrial Hyperplasia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma e......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy